幹細胞市場趨勢

Abstract

The news has been full of industry developments and financial investments in stem cell research in recent weeks. Your company must be aware of the latest developments immediately.

• Researchers Find New Source For Stem Cells That Could End Debate
• Brain stem cells against cancer?
• ' Bio-ink' Printer Transforms Stem Cells
• US delegation divided over stem cells

Stem cells are without doubt the most controversial area of science at the moment. The world markets have latched onto the potential offered by stem cells to modern medicine and, as a result, the research is in the public eye on an almost daily basis. Are you fully informed of the market potential of stem cell work? Do you know which companies and research organisations you must work with now? This report tells you.

So what is all the controversy about? And what products are we likely to see, in what areas and when, if stem cell work continues at pace?

The potential lies in that given the right circumstances, embryonic stem cells could be used to create new tissues and organs for patients whose tissues or organs have been destroyed, damaged, diseased or have simply aged. For example, for patients with heart failure, the aim would be to create new, tailor-made cardiac cells to replace the damaged tissue. For patients with spinal injury, research would be directed at the creation of new spinal tissue which could replace injured nerve tissue allowing the patient to regain mobility in paralysed limbs. What part will your company play in this? Find out today.

However, much of this global effort is currently being thwarted by issues that are restraining progress in a way that has been unparalleled in the biotech and pharmaceutical sector. How can your company get around these problems? What opportunities are there for you? Find out today.

With these obvious frustrations, it is perhaps surprising that so much work on embryonic stem cells, and to a lesser extent adult stem cells, continues but governments and companies around the world are evolving new strategies to overcome these limitations.

One successful product launch will change the face of modern medicine from a situation where treatments and alleviation of suffering are the norm to one where replacement parts are offered routinely.

This unique one-stop-shop of a report is the premier business analysis of the market opportunities. Possible values to the market range from billions to perhaps nothing. If the one product launch fails to deliver or, worse, has damaging side-effects, then the market could just as easily collapse overnight. By reading one report you can put your company to the forefront of stem cell business knowledge.

This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company ' the edge' of your competitors. You can not afford to be without this report from visiongain.

Table of Contents

Chapter 1. Introduction

• 1.1 Introduction
• 1.2 Stem cells
  • 1.2.1 History
  • 1.2.2 Definitions
• 1.3 Embryonic stem (ES) cells
• 1.4 Embryonic germ (EG) cells
  • 1.4.1 Embryonic stem (ES) cells versus embryonic germ (EG) cells
• 1.5 Adult stem cells
  • 1.5.1 Advantages of adult stem cells
  • 1.5.2 Disadvantages of adult stem cells
  • 1.5.3 Adult stem cell plasticity and transdifferentiation
  • 1.5.4 Questions about adult stem cells
• 1.6 Cloning
  • 1.6.1 Therapeutic cloning
  • 1.6.2 Reproductive cloning
  • 1.6.3 Dolly the sheep
  • 1.6.4 Other cloning successes
• 1.7 Tissue engineering
  • 1.7.1 History
  • 1.7.2 Progress
• 1.8 Conclusions

Chapter 2. Key players

• 2.1 Introduction
  • 2.1.1 Novocell
  • 2.1.2 ES Cell International
  • 2.1.3 Reliance Life Sciences
  • 2.1.4 Cytori Therapeutics
  • 2.1.5 Intercytex
• 2.2 Companies that have stem cell lines currently stored at the NIH Human Embryonic Stem Cell Registry in the US
  • 2.2.1 BresaGen
  • 2.2.2 Cellartis
  • 2.2.3 Cythera/ Novocell
  • 2.2.4 ES Cell International (ESI)
  • 2.2.5 Geron
  • 2.2.6 Reliance Life Sciences
• 2.3 Pharmaceutical industry
  • 2.3.1 Amersham
  • 2.3.2 Amgen
  • 2.3.3 AstraZeneca
  • 2.3.4 Johnson & Johnson
  • 2.3.5 Merck
  • 2.3.6 Novartis AG
  • 2.3.7 Schering AG
• 2.4 Key companies - US
  • 2.4.1 Aarstrom Biosciences Inc.
  • 2.4.2 Advanced Cell Technology Inc.
  • 2.4.3 BioE
  • 2.4.4 Cellerant
  • 2.4.5 Cytori Therapeutics
  • 2.4.6 Genentech
  • 2.4.7 Osiris
  • 2.4.8 Stem Cells Inc.
  • 2.4.9 Stem Cell Therapeutics Corp
  • 2.4.10 Titan Pharmaceuticals Inc.
  • 2.4.11 Viacell
• 2.5 Key companies - UK
  • 2.5.1 Angel BioTechnology
  • 2.5.2 Axordia
  • 2.5.3 Epistem
  • 2.5.4 Intercytex
  • 2.5.5 Novathera
  • 2.5.6 Odontis
  • 2.5.7 RegenTec
  • 2.5.8 Reinnervate
  • 2.5.9 ReNeuron
  • 2.5.10 Renovo
  • 2.5.11 Stem Cell Sciences
• 2.6 Key companies - global
  • 2.6.1 Australia
    • 2.6.1.1 Mesoblast Limited
  • 2.6.2 Israel
    • 2.6.2.1 Pluristem
    • 2.6.2.2 BrainStorm Cell Therapeutics
    • 2.6.2.3 Gamida
  • 2.6.3 Thailand
    • 2.6.3.1 TheraVitae
  • 2.6.4 India
    • 2.6.4.1 Stempeutics
  • 2.6.5 Singapore
  • 2.6.6 Sweden
• 2.7 Other companies
  • 2.7.1 Bioheart, Inc.
  • 2.7.2 Aldagen
  • 2.7.3 Cellular Dynamics International
  • 2.7.4 RhinoCyte
  • 2.7.5 Stem Cell Innovations
  • 2.7.6 StemCell Technologies
  • 2.7.7 Vesta Therapeutics
  • 2.7.8 Vistagen Therapeutics
• 2.8 Conclusions

Chapter 3. The Market

• 3.1 Introduction
• 3.2 The Global burden of disease
• 3.3 Numbers of patients
• 3.4 Cost of illness
• 3.5 Major clinical applications
  • 3.5.1 Cardiac applications
  • 3.5.2 Other circulatory applications
  • 3.5.3 Cosmetic applications
  • 3.5.4 Dermatological applications
  • 3.5.5 Endocrine applications
  • 3.5.6 Hepatic applications
  • 3.5.7 Neural applications
  • 3.5.8 Optical applications
  • 3.5.9 Orthodontic applications
  • 3.5.10 Orthopaedic applications
  • 3.5.11 Renal applications
  • 3.5.12 Other applications
• 3.6 Regenerative medicine market
  • 3.6.1 Stem cell market
  • 3.6.2 Media coverage
  • 3.6.3 Tissue engineering
• 3.7 Conclusions

Chapter 4. Issues

• 4.1 Introduction
• 4.2 Ethical Issues
  • 4.2.1 The Ethics of how life is defined
  • 4.2.2 The Ethics of using stem cells
• 4.3 Social Issues
  • 4.3.1 Tissue source
  • 4.3.2 Hybrids
  • 4.3.3 Long term implications of stem cell research
• 4.4 Moral issues
• 4.5 Religious issues
  • 4.5.1 Catholicism
  • 4.5.2 Protestantism
  • 4.5.3 Judaism
  • 4.5.4 Islam
  • 4.5.5 Hinduism
• 4.6 Political issues
  • 4.6.1 US
• 4.7 Conclusions

Chapter 5. Regulations and patents

• 5.1 Introduction
• 5.2 Regulatory issues
  • 5.2.1 UK Government initiatives
  • 5.2.2 UK Stem cell bank
  • 5.2.3 UK - Current regulations
  • 5.2.4 US Government initiatives
    • 5.2.4.1 History
    • 5.2.4.2 Appropriations Bill, HR 3061 (Sec. 510)
  • 5.2.5 US Current regulations
  • 5.2.6 Ongoing controversy
  • 5.2.7 Political landscape
  • 5.2.8 Cell line viability
  • 5.2.9 Xenotransplantation
  • 5.2.10 Rest of World
  • 5.2.11 Europe
  • 5.2.12 Asia
    • 5.2.12.1 Japan
    • 5.2.12.2 China
    • 5.2.12.3 Singapore
    • 5.2.12.4 India
    • 5.2.12.5 South Korea
  • 5.2.13 Australia
    • 5.2.14.1 Canada
    • 5.2.14.2 South America
  • 5.2.13 Australasia
  • 5.2.14 Canada and South America
  • 5.2.15 Middle East
  • 5.2.16 Africa
• 5.3 Conclusions
• 5.4 Patenting Issues
  • 5.4.1 Background
  • 5.4.2 Patenting - Europe
  • 5.4.3 Patenting - UK
    • 5.4.3.1 Processes for obtaining stem cells from human embryos
    • 5.4.3.2 Human totipotent cells
    • 5.4.3.3 Human embryonic pluripotent cells
  • 5.4.4 Patenting - USA
    • 5.4.4.1 Wisconsin Alumni Research Foundation (WARF)
    • 5.4.4.2. Geron
  • 5.4.5 Patenting controversy
  • 5.4.6 Patenting - global
• 5.5 Conclusions

Chapter 6. Trends, Drivers and Opportunities

• 6.1 Introduction
• 6.2 Stem Cell Research - SWOT analysis
  • 6.2.1 Strengths
  • 6.2.2 Weaknesses
  • 6.2.3 Opportunities
  • 6.2.4 Threats
• 6.3 Trends
  • 6.3.1 Portfolio diversification
  • 6.3.2 Strong proprietary rights
  • 6.3.3 Strategic partnerships
• 6.4 Drivers
  • 6.4.1 Funding
  • 6.4.2 Results
• 6.5 Opportunities
  • 6.5.1 Suppliers to the stem cell industry
  • 6.5.2 Cord blood banking
• 6.6 Conclusions

Chapter 7. Stem cell research funding

• 7.1 Introduction
• 7.2 Charities and research councils
  • 7.2.1 Wellcome Trust/ Juvenile Diabetes Research Foundation
  • 7.2.2 Wellcome Trust/ Medical Research Council/ Wolfson Foundation
  • 7.2.3 Juvenile Diabetes Research Foundation (JDRF)
• 7.3 Private funds
  • 7.3.1 The Starr Foundation
  • 7.3.2 Ansary Center for Stem Cell Therapeutics
  • 7.3.3 Johns Hopkins.
  • 7.3.4 University of Texas Health Centre
  • 7.3.5 University of California, San Francisco (UCSF)
• 7.4 Public funds
  • 7.4.1 Venture Capital
  • 7.4.2 Other public funds
  • 7.4.3 California
  • 7.4.4 New Jersey
  • 7.4.5 Massachusetts
  • 7.4.6 Connecticut
  • 7.4.7 Illinois
  • 7.4.8 Maryland
  • 7.4.9 Ohio
  • 7.4.10 Others
  • 7.4.11 European Union
• 7.5 Conclusions

Chapter 8. Conclusions - the future of the stem cell market

• 8.1 Introduction
• 8.2 Progress
  • 8.2.1 Science
  • 8.2.2 Media
  • 8.2.3 Geography
  • 8.2.4 Funding
  • 8.2.5 Patenting
  • 8.2.6 Politics
• 8.3 Recommendations

List of tables

• Table 1.1 Key achievements in stem cell research
• Table 1.2 Diseases and conditions treated with adult stem cell therapies
• Table 2.1 Organisations currently listed as the supplier of stem cell lines to the NIH Human Embryonic Stem Cell Registry
• Table 3.1 The world top 20 threats to health in 2002 and projected 2030
• Table 3.2 Number of potential patients in the US eligible for stem cell therapy
• Table 3.3 Annual direct expenditure in the US for leading diseases and conditions
• Table 3.4 Top surgical and non-surgical cosmetic procedures for men and women (2005)
• Table 5.1 Representative state-wide initiatives regarding the application of stem cell research
• Table 5.2 EU member states legislation (2006)

List of figures

• Figure 1.1 Number of papers published per annum (1996-2006)
• Figure 1.2 Schematic of embryonic stem cell differentiation
• Figure 1.3 Lung cells derived from human embryonic stem cells
• Figure 1.4 Foetal neural stem cells
• Figure 1.5 Schematic of embryonic tissue differentiation
• Figure 5.1 Published patents (1997 - 2005), Title search: "Stem cell*", "Embryonic stem cell*" and "Human embryonic stem cell*"
• Figure 5.2 Number of key patent families (2000 - 2005)
• Figure 7.1 Current translation pathway for stem cell research to commercialization

Organisations Listed

• Aarstrom Biosciences Inc.
• Acorda Therapeutics
• Advanced BioHealing, Inc.
• Advanced Cell Technology Inc.
• Aldagen, Inc.
• American Society of Plastic Surgeons
• Amersham
• Amgen
• Angel BioTechnology
• Ansary Center for Stem Cell Therapeutics
• Arthritis Research Campaign, UK
• AstraZeneca
• Athersys
• Axordia
• Bart' s and The London NHS Trust, UK
• BioE
• Bioheart, Inc.
• Biotechnology and Biological Sciences Research Council, UK
• BrainStorm Cell Therapeutics
• BresaGen
• Burnham Institute for Medical Research
• The California Family Bioethics Council
• California Institute for Regenerative Medicine
• Cellartis
• CellCura
• Cellerant
• Cellular Dynamics International
• The Cellulite Clinic
• Center for Stem Cell and Regenerative Medicine, Ohio
• Cordlife
• Cythera/ Novocell
• Cytori Therapeutics
• Department of Health and Human Services, US
• Epistem
• ES Cell International (ESI)
• European Patent Office
• Fisher
• Food and Drug Administration, US
• Gamida
• Genentech
• Genzyme
• Geron
• GlobalStem Inc
• Human Fertilisation and Embryology Authority, UK
• Illinois Regenerative Medicine Institute
• Institute for Regenerative Medicine
• Intercytex
• Invitrogen
• The Joan and Sanford I Weill Medical Centre
• Johns Hopkins University
• Johnson and Johnson
• Juvenile Diabetes Research Foundation
• King' s College, London
• Maryland Technology Development Corporation
• Mediatech Inc
• Medical Research Council, UK
• Medra Clinic
• Memorial Sloan-Kettering Cancer Centre
• Merck
• Mesoblast Limited
• Nabi Medspa
• The National Academies, US
• The National Institutes of Health, US
• National Health Service
• National Science Foundation
• National Tax Limitation Committee
• Neuronova
• New Jersey Stem Cell Institute
• Novartis AG
• Novathera
• Novocell
• Odontis
• Organogenesis
• Osiris
• Pluristem
• RegenTec
• Reinnervate
• Reliance Life Sciences
• ReNeuron
• Renovo
• RhinoCyte, Inc.
• Rockefeller University
• Roslin Institute
• Royal College of Obstetrics and Gynaecologists, UK
• Schering AG
• Sigma-Aldrich
• Smith and Nephew
• The Starr Foundation
• Stem Cells Inc.
• Stem Cell Innovations
• StemCell Technologies Inc.
• Stem Cell Therapeutics Corp
• Stem Cell Sciences
• StemCo Biomedical
• Stempeutics
• Tengion
• TheraVitae
• Titan Pharmaceuticals Inc.
• Tulane University
• UK Stem Cell Bank
• United States Patents and Trademark Office
• University of Maryland
• University of Massachusetts
• University of Newcastle
• University of San Francisco, California
• University of Texas Health Centre
• University of Wisconsin
• Vesta Therapeutics Inc.
• Viacell
• Vistagen Therapeutics Inc.
• Wellcome Trust, UK
• WiCell Research Institute, US
• Wisconsin Alumni Research Foundation
• Wisconsin State Laboratory of Hygiene
• Wolfson Foundation, UK
• World Health Organisation